Roche presented Phase 3 data showing ctDNA‑guided adjuvant Tecentriq prolonged survival for a subset of bladder cancer patients identified as high risk by a circulating tumor DNA test. The data, presented at ESMO, illustrate how blood‑based biomarkers can stratify recurrence risk and select patients for adjuvant immunotherapy. Separately, the DYNAMIC‑III international trial reported ctDNA utility in Stage 3 colon cancer by tailoring postsurgical treatment, supporting a precision approach that spares low‑risk patients chemotherapy while intensifying therapy for ctDNA‑positive individuals. Together the readouts strengthen the clinical case for integrating ctDNA into routine postsurgical decision‑making and will influence regulatory and reimbursement discussions around blood‑based tumor profiling.